Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy
- PMID: 26823498
- DOI: 10.1161/CIRCHEARTFAILURE.115.002667
Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy
Abstract
Background: There are conflicting data regarding the efficacy of cardiac resynchronization therapy (CRT) in patients with heart failure (HF) and without left bundle branch block.
Methods and results: We evaluated the long-term clinical outcomes of 537 non-left bundle branch block patients with mild HF enrolled in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) study by QRS duration or morphology further stratified by PR interval. At 7 years of follow-up, the cumulative probability of HF hospitalization or death was 45% versus 56% among patients randomized to implantable cardioverter-defibrillator and CRT with defibrillator (CRT-D), respectively (P=0.209). Multivariable-adjusted subgroup analysis by QRS duration showed that patients from the lower quartile QRS duration group (≤ 134 ms) experienced 2.4-fold (P=0.015) increased risk for HF hospitalization or death with CRT-D versus implantable cardioverter-defibrillator only therapy, whereas the effect of CRT-D in patients from the upper quartiles group (QRS>134 ms) was neutral (hazard ratio [HR] =0.97, P=0.86; P value for interaction =0.024). In a second analysis incorporating PR interval, patients with prolonged QRS (>134 ms) and prolonged PR (>230 ms) were protected with CRT-D (HR=0.31, P=0.003), whereas the association was neutral with prolonged QRS (>134 ms) and shorter PR (≤ 230 ms;, HR=1.19, P=0.386; P value for interaction =0.002). The effect was neutral, regardless of morphology, right bundle branch block (HR=1.01, P=0.975), and intraventricular conduction delay (HR=1.31, P=0.172).
Conclusions: Overall, patients with mild HF but without left bundle branch block morphology did not derive clinical benefit with CRT-D during long-term follow-up. Relatively shorter QRS was associated with a significantly increased risk with CRT-D relative to implantable cardioverter-defibrillator -only.
Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00180271, NCT01294449, and NCT02060110.
Keywords: bundle-branch block; heart failure; implanted cardioverter–defibrillator; morbidity/mortality; resynchronization.
© 2016 American Heart Association, Inc.
Similar articles
-
Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.J Am Heart Assoc. 2015 Jun 29;4(7):e002013. doi: 10.1161/JAHA.115.002013. J Am Heart Assoc. 2015. PMID: 26124205 Free PMC article. Clinical Trial.
-
PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy.Circ Arrhythm Electrophysiol. 2014 Aug;7(4):645-51. doi: 10.1161/CIRCEP.113.001299. Epub 2014 Jun 24. Circ Arrhythm Electrophysiol. 2014. PMID: 24963007 Clinical Trial.
-
Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction.Circ Heart Fail. 2015 Jul;8(4):725-32. doi: 10.1161/CIRCHEARTFAILURE.115.002082. Epub 2015 Jun 2. Circ Heart Fail. 2015. PMID: 26038537
-
The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients.Europace. 2013 Jul;15(7):992-1001. doi: 10.1093/europace/eus419. Epub 2013 Feb 17. Europace. 2013. PMID: 23419662 Review.
-
An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure.Eur Heart J. 2013 Dec;34(46):3547-56. doi: 10.1093/eurheartj/eht290. Epub 2013 Jul 29. Eur Heart J. 2013. PMID: 23900696 Free PMC article. Review.
Cited by
-
Cardiac Resynchronization Therapy-Emerging Therapeutic Approaches.Curr Treat Options Cardiovasc Med. 2018 Mar 6;20(3):20. doi: 10.1007/s11936-018-0614-2. Curr Treat Options Cardiovasc Med. 2018. PMID: 29508156 Review.
-
Shortening of time-to-peak left ventricular pressure rise (Td) in cardiac resynchronization therapy.ESC Heart Fail. 2021 Dec;8(6):5222-5236. doi: 10.1002/ehf2.13601. Epub 2021 Sep 12. ESC Heart Fail. 2021. PMID: 34514746 Free PMC article.
-
Non-response to Cardiac Resynchronization Therapy.Curr Heart Fail Rep. 2018 Oct;15(5):315-321. doi: 10.1007/s11897-018-0407-7. Curr Heart Fail Rep. 2018. PMID: 30097910 Review.
-
2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure.J Arrhythm. 2023 Aug 2;39(5):681-756. doi: 10.1002/joa3.12872. eCollection 2023 Oct. J Arrhythm. 2023. PMID: 37799799 Free PMC article.
-
Brazilian Guidelines for Cardiac Implantable Electronic Devices - 2023.Arq Bras Cardiol. 2023 Jan 23;120(1):e20220892. doi: 10.36660/abc.20220892. Arq Bras Cardiol. 2023. PMID: 36700596 Free PMC article. English, Portuguese. No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous